c-myc oncogene product expression and prognosis in operable breast cancer. by Locker, A. P. et al.
Br. J. Cancer (1989), 60, 669 672 1989
C-myc oncogene product expression and prognosis in operable breast
cancer
A.P. Locker', C.S. Dowle', I.O. Ellis', C.W. Elston', R.W. Blamey', K. Sikora2, G. Evan2 &
R.A. Robins3
'Nottingham City Hospital, Hucknall Road, Nottingham NGS IPB, UK; 2Ludwig Institutefor Cancer Research, Cambridge, UK; and3Cancer Research Campaign Laboratories, Nottingham, UK.
Summary The 62 kDa protein product of the c-myc oncogene (p62 c-myc) is thought to be involved in the
control of normal cellular proliferation and differentiation. We have measured oncoprotein levels using a flow
cytometric assay in 141 operable breast cancers and have correlated levels with prognostic variables, patient
survival and disease free intervals. High levels of p62 c-myc were associated with well differentiated tumours.
There was no correlation with tumour DNA index, lymph node or oestrogen receptor status. C-myc
oncoprotein levels were not predictive of patient survival or disease free interval. This relationship of
oncoprotein levels with tumour histological grade is in keeping with the suggestion that the c-myc oncogene is
important in the control of cellular differentiation. The other findings imply that measurement of c-myc
oncoprotein levels does not yield useful prognostic information.
Cellular oncogenes resembling viral oncogenes are present in
normal cells where they encode proteins that act as receptors,
intracellular signal transducers or growth factors. Oncogene
products are thus important in the control of normal cellular
development and division. Changes in oncogene expression
occur during normal wound repair (Goyette et al., 1983) and
embryogenesis (Muller et al., 1982). Changes in oncogene
control and expression may also lead to, or be associated
with, malignant transformation.
The c-myc oncoprotein is associated with cell division and
differentiation as c-myc mRNA increases as culture cells are
stimulated into division (Kelly et al., 1983). It has a short
half-life and has been shown to be nuclear associated (Pers-
son & Leder, 1984), which is in keeping with a proposed role
in cell cycle control. The aim of this study was to confirm
that c-myc oncoprotein levels could be quantified in the
nuclei of breast cancers. We also wished to determine wheth-
er a correlation existed between oncoprotein levels, tumour
prognostic factors, patient survival and disease-free interval.
Patients and methods
One hundred and forty-one patients were studied. All had
undergone simple or subcutaneous mastectomy as the pri-
mary treatment for their breast cancer between 1974 and
1976 at the Nottingham City Hospital. Lymph node sampl-
ing was performed in all cases. The nodes sampled were low
axillary, apical axillary and internal mammary (via the se-
cond interspace) at the time of initial surgery. Three lymph
node stages can be identified based on the involvement of
nodes with metastatic tumour. These are: stage 1, no nodal
involvement; stage 2, low axillary node involvement alone;
stage 3, apical or internal mammary node involved alone or
in any other combination.
Antibodies to the c-myc oncoprotein have been generated
by peptide immunisation (Evan et al., 1985). The DNA
sequence of the c-myc gene was used to deduce the amino
acid sequence of the oncoprotein, and mice were immunised
to produce monoclonal antibodies. A number of antibodies
have been produced and one of them can be used to detect
p62 c-myc in archival pathological material. We have used
this antibody (myc 1-6E10) to characterise oncoprotein levels
in paraffin embedded primary breast cancer.
We used the technique of simultaneously measuring p62
c-myc and DNA as described in detail by Watson et al.
(1985). In brief, 40JM sections were cut from formalin fixed
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paraffin embedded tumour. Sections were dewaxed in xylene
and then rehydrated through a decreasing alcohol gradient. Pepsin digestion (0.5% pepsin in 0.9% saline at pH 1.5)
released the nuclei which were washed, filtered and resus-
pended in phosphate buffered saline.
Varying dilutions (1:20, 1:50, 1:100, 1:200) of mouse anti
p62 c-myc monoclonal antibody (MYC 1-6E10) were then
added to aliquots of the nuclear suspension. Following incu-
bation for 45 min all samples were centrifuged and the super-
natant removed. To each was added 10 ll of fluorocein
isothiocyanate (FITC) conjugated anti mouse immuno-
globulin diluted 1:50 (Dakopatts, Denmark). After 1 h all
samples were suspended in 0.5 ml of a solution containing
propidium iodide (50 figml-'). This is a fluorescent nucleic
acid dye which counterstains DNA red against the green
fluorescence from the staining of the p62 c-myc. Two cont-
rols were used; one with propidium iodide and FITC rabbit
anti-mouse immunoglobulin and a second with propidium
iodide alone.
All samples were then analysed on a FACS IV (Becton
Dickinson) flow cytometer using an argon laser light source
to excite fluorescence. For each patient the maximum green
fluorescence level from the four dilutions of antibody was
considered to be directly proportional to the p62 c-myc level,
once the control fluorescence value of the FITC rabbit anti-
mouse control had been subtracted. The oncoprotein levels
are thus expressed in fluorescence units (FU). The tumour
DNA ploidy was expressed as the DNA index, which is the
ratio of the tumour cell peak channel number to the control
cell peak channel number. In this study the internal control
cells were normal lymphocytes and stromal cells which were
present in adequate quantities in the paraffin embedded tu-
mour material. By definition a value of 1.0 is taken to
represent a diploid tumour, a value greater than this a hyper-
diploid or aneuploid lesion.
We have correlated c-myc oncoprotein levels measured in
this way with tumour grade, as defined by Elston's
modification of the Bloom and Richardson criteria (Elston,
1987). Grade was assessed by allocation of individual scores
from one to three based on increasing severity of three
features: nuclear pleomorphism (small regular nuclei, 1; to
large nuclei of variable size 3), tubule formation (present in
>75% of the tumour, 1; to present in < 10% of tumour, 3),
and mitotic frequency (number seen per 10 high power mic-
roscopic fields <10, 1; to >20, 3). The overall grade is
derived from summation of the individual scores as follows:
3-5, grade I; 6-7, grade II; 8-9, grade III. With experience
intra-observer variability can be reduced to very low levels.
With training inter-observer variability can also be reduced
to acceptable levels. To confirm the prognostic value of
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histological grading within this series of patients, survival
curves have been constructed for each of the three grades
(Figure 2).
Oncoprotein levels were also correlated with DNA index,
lymph node and oestrogen receptor status (ER). ER status
was measured by the dextran coated charcoal method (May-
nard & Griffiths, 1978), a value of >5 fmol mg-' cytosol
protein being considered positive.
Life table analysis (Goldstone, 1985) was used to construct
survival curves, with Mantel's analysis (Mantel, 1966) to
compare the difference between groups.
Results
The range of measured green fluorescence for the 141 tu-
mours was 2.3-480 fluorescence units (median 49.2 FU).
Examples of bivariate analysis of c-myc staining (green fluor-
escence) against DNA staining (red fluorescence) for both
diploid and an aneuploid tumour are seen in Figure 1.
For subsequent analysis the c-myc staining (green fluor-
escence values) were divided into tertile groups (i.e. 47 tu-
mours in each) deemed low, moderate and high.
Histological grade
The histopathological grade had been recorded in all of the
141 patients. There was a correlation between p62 c-myc
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levels and tumour grade: lower levels of p62 c-myc being
associated with a poorer grade P<0.05 (Table I).
DNA index
Eighty-four patients had diploid tumours (DNA index = 1.0),
57 patients had aneuploid tumours (DNA index> 1.0). There
was no correlation between DNA index and p62 c-myc levels
(Table II).
Oestrogen receptor (ER) status
ER status was known in 126 patients and the relationship
with oncoprotein levels is seen in Table III. There is a
tendency for tumours producing low levels of oncoprotein to
be ER negative (25 of 40 or 62% of patients). This just failed
to reach statistical significance.
Lymph node status
In 137 patients the lymph node status was available. No
correlation was observed between nodal status at the time of
surgery and the tumour oncoprotein levels (Table IV).
Survival
Life table analysis demonstrates no significant association
between overall patient survival or disease-free interval and
tumour oncoprotein levels (Figures 3 and 4).
Table I Histological grade versus c-myc oncoprotein tertiles
(n= 141)
Histological grade
c-myc
tertiles 1 2 3
Low 3 14 30
Moderate 9 20 18
High 9 22 16
x2= 10.66 (4 d.f.); P = <0.05.
Table II DNA index versus c-myc oncoprotein tertiles (n = 141)
DNA index
c-myc
tertiles 1.0 > 1.0
Low 32 15
Moderate 28 19
High 25 22
X2 = 2.19 (2 d.f.); P = n.s.
b
16 32 48 64
Red flu. (3)
Figure 1 Bivariate analysis of c-myc staining against DNA stain-
ing. Red fluorescence (x axis) from propidium iodide staining is
plotted against green fluorescence (y axis, indirect immuno-
fluorescence for c-myc) for diploid (a) and aneuploid (b) tumours.
In the aneuploid tumour, the majority of c-myc staining is
associated with the aneuploid population.
Table III Oestrogen receptor status versus c-myc oncoprotein tertiles
(n = 126)
Oestrogen receptor status c-myc
tertiles + ve -ve
Low 15 25
Moderate 25 16
High 22 23
X2 = 4.46 (2 d.f.); P = n.s.
Table IV Lymph node status versus c-myc oncoprotein tertiles
(n= 131)
Nodal status
c-myc
tertiles 1 2 3
Low 24 16 7
Moderate 21 12 9
High 18 14 10
X2= 1.56 (4 d.f.); P = n.s.
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Figure 2 Patient survival versus histological grade.
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Figure 3 Patient survival versus c-myc oncoprotein tertiles.
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Figure 4 Patient disease free interval versus c-myc oncoprotein
tertiles.
In normal resting cells oncogenes appear to be transcribed at
low levels (Hamlyn & Sikora, 1983) and this can make the
study of their products difficult. The c-myc oncogene product
has, however, been quantified by immunohistological meth-
ods and by flow techniques as utilised by us but previously
described in detail elsewhere (Watson et al., 1985). This study
has confirmed that the c-myc protein product can be quanti-
fied in archival breast cancer using flow cytometry.
The c-myc oncogene is thought to be important in control-
ling cell division and differentiation in both normal and
malignant tissue. Following partial hepatectomy and during
differentiations of marrow stem cells differing oncogene tran-
scriptional patterns have been noted (Hamlyn & Sikora,
1983). Large quantities of p62 c-myc oncoprotein occur tran-
siently during the normal differentiation of testicular germ
cells. A number of studies (Greenberg & Ziff, 1984; Kelly et
al., 1984; Makino et al., 1984; Hann et al., 1985; Thompson
et al., 1985; Rabbitts et al., 1985; Stewart et al., 1986) have
provided evidence suggesting that the p62 c-myc.oncogene in
some way controls the passage of cells from the resting (GO
phase) to the dividing (GI phase) of the cell cycle.
We have shown that high levels of c-myc oncoprotein are
associated with well differentiated breast tumours and low
levels with poorly differentiated tumours. This finding is in
keeping with a study in testicular cancer (Sikora et al., 1985)
where the most undifferentiated teratomas contained low
levels of c-myc oncoprotein. Low levels of c-myc oncoprotein
have also been shown to be associated with poorly
differentiated colonic tumours (Sikora et al., 1987; Watson et
al., 1987). This lends support to the theory that the c-myc
oncogene is associated with the control of cell differentiation.
We have not demonstrated any significant association be-
tween oncoprotein levels and tumour ploidy suggesting that
oncoprotein production is not directly linked to total nuclear
DNA content. The trend of low oncoprotein tumours being
more likely to be oestrogen receptor negative (Table III),
although not statistically significant, is interesting. This result
is clearly in keeping with the less favourable prognosis in
oestrogen receptor negative patients (Maynard et al., 1978).
The p62 c-myc oncoprotein levels are not related to either
overall patient survival (Figure 3) or disease free interval
(Figure 4).
Our finding of c-myc oncoprotein levels not being related
to prognosis is disappointing but is in keeping with a recently
published study investigating c-myc oncoprotein levels using
an identical flow cytometric assay in archival biopsies of
uterine cervix neoplasia (Hendy-Ibbs et al., 1987). This study
also failed to show any relationship between oncoprotein levels and patient prognosis and like ourselves no relation-
ship with disease stage.
There are several explanations for the lack of association
between patient survival and tumour oncoprotein levels, des-
pite the latter's significant relationship with tumour histo-
pathological grade. Although we have demonstrated the pro-
gnostic value of histopathological grading in the patients in
this study (Figure 2), it is only one of a number of variables
known to influence patients' prognosis. Furthermore, it is
possible that oncoprotein levels have a better association
with one of the components of histological grade rather than
overall differentiation.
In conclusion our study has demonstrated a relationship
between histopathological tumour grade and c-myc onco-
protein levels in primary breast cancer. No other associations
were observed and in particular oncoprotein levels are not
predictive of survival or disease-free interval.
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